Evercore ISI Group Maintains In-Line on Hims & Hers Health, Raises Price Target to $27

Benzinga · 2d ago
Evercore ISI Group analyst Mark Mahaney maintains Hims & Hers Health (NYSE:HIMS) with a In-Line and raises the price target from $24 to $27.